Treatment carries significant risks: New Alzheimer’s drug Leqembi could reach Luxembourg by mid-2025

While the EU’s approval of Leqembi offers new hope for Luxembourg’s Alzheimer’s patients, medical experts warn the expensive treatment only helps early-stage cases and carries potentially life-threatening side effects that exclude many candidates.